Optimal usage of radium-223 in metastatic castration-resistant prostate cancer

被引：14
|
作者：
Cha, Tai-Lung [1 ]
Wu, Tony Tong-Lin [2 ]
Vogelzang, Nicholas John [3 ,13 ]
Huang, Chao-Yuan [4 ]
Huang, Shu-Pin [5 ]
Lin, Chia-Chi [6 ]
Ou, Yen-Chuan [7 ]
Pang, See-Tong [8 ]
Shen, Daniel Heung-Yuan [9 ]
Wu, Wen-Jeng [10 ]
Chang, Wayne Yen-Hwa [11 ,12 ]
机构：
[1] Natl Def Med Ctr, Div Urol, Dept Surg, Triserv Gen Hosp, Taipei, Taiwan
[2] Kaohsiung Vet Gen Hosp, Div Urol, Dept Surg, Kaohsiung, Taiwan
[3] Univ Nevada, Sch Med, Med Oncol Comprehens Canc Ctr Nevada, Las Vegas, NV 89154 USA
[4] Natl Taiwan Univ Hosp, Dept Urol, Taipei, Taiwan
[5] Kaohsiung Med Univ, Dept Urol, Chung Ho Mem Hosp, Kaohsiung, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[7] Taichung Vet Gen Hosp, Div Urol, Dept Surg, Taichung, Taiwan
[8] Chang Gung Mem Hosp, Div Urol, Dept Surg, Linkou, Taiwan
[9] Natl Def Med Ctr, Dept Nucl Med, Triserv Gen Hosp, Taipei, Taiwan
[10] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Urol, Chung Ho Mem Hosp, Kaohsiung, Taiwan
[11] Taipei Vet Gen Hosp, Div Gen Urol, Dept Urol, Taipei, Taiwan
[12] Natl Yang Ming Univ, Dept Urol, Sch Med, Taipei, Taiwan
[13] Comprehens Canc Ctr Nevada, 3730 S Eastern Ave, Las Vegas, NV 89169 USA
来源：
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | 2017年 / 116卷 / 11期
关键词：
Radium chloride Ra 223; Radiopharmaceuti-cals; PAINFUL BONE METASTASES; DOUBLE-BLIND; CLINICAL-EXPERIENCE; PHASE-III; CHLORIDE; SURVIVAL; THERAPY; MULTICENTER; PALLIATION; DICHLORIDE;
D O I：
10.1016/j.jfma.2017.04.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Radium-223 is a first-in-class alpha-emitting radiopharmaceutical that targets bone metastases associated with metastatic castration-resistant prostate cancer (mCRPC). In the pivotal phase III trial ALSYMPCA, radium-223 significantly increased overall survival (OS), compared with placebo (median 14.9 vs 11.3 months; hazard ratio 0.70; 95% CI 0.58-0.83; p < 0.001), in patients with mCRPC and symptomatic bone metastasese-with a comparable safety profile.
引用
下载
收藏
页码：825 / 836
页数：12
相关论文
共 50 条
  • [21] EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer
    Thorsten D. Poeppel
    Daria Handkiewicz-Junak
    Michael Andreeff
    Alexander Becherer
    Andreas Bockisch
    Eva Fricke
    Lilli Geworski
    Alexander Heinzel
    Bernd J. Krause
    Thomas Krause
    Markus Mitterhauser
    Wilfried Sonnenschein
    Lisa Bodei
    Roberto C. Delgado-Bolton
    Michael Gabriel
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 824 - 845
  • [22] Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer
    Saylor, Philip J.
    Otani, Keisuke
    Balza, Rene
    Ukleja, Jacob
    Pleskow, Haley
    Fisher, Rebecca
    Kusaka, Erika
    Otani, Yukako S.
    Badusi, Priscilla Oluwakemi
    Smith, Matthew R.
    Meneely, Erika
    Olivier, Kara
    Lowe, Alarice C.
    Toner, Mehmet
    Maheswaran, Shyamala
    Haber, Daniel A.
    Yeap, Beow Y.
    Lee, Richard J.
    Miyamoto, David T.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [23] Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223
    Rodriguez-Vida, A.
    Torregrosa, M. D.
    Pinto, A.
    Climent, M. A.
    Olmos, D.
    Carles, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (06): : 679 - 686
  • [24] A Case of Success: Complete Response to Radium-223 in Metastatic Castration-Resistant Prostate Cancer
    Pinho, Ines Soares de
    Esperanca-Martins, Miguel
    Machado, Barbara
    Damaso, Sara
    Bras, Raquel Lopes
    Cantinho, Guilhermina
    Fernandes, Isabel
    Costa, Luis
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [25] EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer
    Poeppel, Thorsten D.
    Handkiewicz-Junak, Daria
    Andreeff, Michael
    Becherer, Alexander
    Bockisch, Andreas
    Fricke, Eva
    Geworski, Lilli
    Heinzel, Alexander
    Krause, Bernd J.
    Krause, Thomas
    Mitterhauser, Markus
    Sonnenschein, Wilfried
    Bodei, Lisa
    Delgado-Bolton, Roberto C.
    Gabriel, Michael
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (05) : 824 - 845
  • [26] Predictors for Survival After Radium-223 Treatment for Castration-Resistant Metastatic Prostate Cancer
    Anderson, E.
    Wong, W. W.
    Mohammadi, H.
    Daniels, T. B.
    Vora, S.
    Schild, S. E.
    Keole, S. R.
    Choo, C. R.
    Tzou, K. S.
    Bryce, A.
    Ho, T. H.
    Quevedo, F. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E255 - E255
  • [27] Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale
    Sedhom, Ramy
    Antonarakis, Emmanuel S.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 : S341 - S345
  • [28] Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer
    Buroni, Federica Eleonora
    Persico, Marco Giovanni
    Pasi, Francesca
    Lodola, Lorenzo
    Nano, Rosanna
    Aprile, Carlo
    ANTICANCER RESEARCH, 2016, 36 (11) : 5719 - 5730
  • [29] Radium-223 in metastatic castration-resistant prostate cancer: current status and future perspectives
    Wyndaele D.N.J.
    Tijdschrift voor Urologie, 2020, 10 (6-7) : 131 - 140
  • [30] Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
    Michel L. Peters
    Claudine de Meijer
    Dirk Wyndaele
    Walter Noordzij
    Annemarie M. Leliveld-Kors
    Joan van den Bosch
    Pieter H. van den Berg
    Agni Baka
    Jennifer G. Gaultney
    Applied Health Economics and Health Policy, 2018, 16 : 145 - 145
12345